{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:28:56Z","timestamp":1793053736499,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["204998\/Z\/16\/Z"],"award-info":[{"award-number":["204998\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Multiparametric MRI localizes cancer in the prostate, allowing for MRI guided biopsy (MRI-GB) 43 alongside transrectal ultrasound-guided systematic biopsy (TRUS-GB). Three MRI-GB approaches exist; visual estimation (COG-TB); fusion software-assisted (FUS-TB) and MRI \u2018in-bore\u2019 biopsy (IB-TB). It is unknown whether any of these are superior.<\/jats:p>\n                <jats:p>We conducted a systematic review and meta-analysis to address three questions. First, whether MRI-GB is superior to TRUS-GB at detecting clinically significant PCa (csPCa). Second, whether MRI-GB is superior to TRUS-GB at avoiding detection of insignificant PCa. Third, whether any MRI-GB strategy is superior at detecting csPCa.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A systematic literature review from 2015 to 2019 was performed in accordance with the START recommendations. Studies reporting PCa detection rates, employing MRI-GB and TRUS-GB were included and evaluated using the QUADAS-2 checklist. 1553 studies were found, of which 43 were included in the meta-analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For csPCa, MRI-GB was superior in detection to TRUS-GB (0.83 vs. 0.63 [<jats:italic>p<\/jats:italic>\u2009=\u20090.02]). MRI-GB was superior in detection to TRUS-GB at avoiding detection of insignificant PCa. No MRI-GB technique was superior at detecting csPCa (IB-TB 0.87; COG TB 0.81; FUS-TB 0.81, [<jats:italic>p<\/jats:italic>\u2009=\u20090.55]). There was significant heterogeneity observed between the included studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with suspected PCa on MRI, MRI-GB offers superior rates of csPCa detection and reduces detection of insignificant PCa compared to TRUS-GB. No individual MRI-GB technique was found to be better in csPCa detection. Prospective adequately powered randomized controlled trials are required.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41391-021-00449-7","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T14:15:42Z","timestamp":1632233742000},"page":"174-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4923-572X","authenticated-orcid":false,"given":"E. J.","family":"Bass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pantovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4033-7508","authenticated-orcid":false,"given":"M. J.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3933-9207","authenticated-orcid":false,"given":"S.","family":"Loeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. R.","family":"Rastinehad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2553-5816","authenticated-orcid":false,"given":"M.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-3094","authenticated-orcid":false,"given":"Rhian","family":"Gabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-6723","authenticated-orcid":false,"given":"H. U.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"449_CR1","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, EL-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815\u201322.","journal-title":"Lancet"},{"key":"449_CR2","unstructured":"European Association of Urology. Guidelines: Prostate Cancer. Available from: https:\/\/uroweb.org\/guideline\/prostate-cancer\/?type=summary-of-changes. Accessed 6th May 2020."},{"key":"449_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.juro.2018.01.071","volume":"200","author":"AB Rosenkrantz","year":"2018","unstructured":"Rosenkrantz AB, Hemingway J, Hughes DR, Duszak R Jr, Allen B Jr, Weinreb JC. Evolving use of prebiopsy prostate magnetic resonance imaging in the medicare population. J Urol. 2018;200:89\u201394.","journal-title":"J Urol"},{"key":"449_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.urology.2018.04.007","volume":"117","author":"W Liu","year":"2018","unstructured":"Liu W, Patil D, Howard DH, Moore RH, Wang H, Sanda MG, et al. Adoption of prebiopsy magnetic resonance imaging for men undergoing prostate biopsy in the united states. Urology. 2018;117:57\u201363.","journal-title":"Urology"},{"key":"449_CR5","unstructured":"Prostate Cancer United Kingdom. mpMRI before biopsy \u2013 a step change in prostate cancer diagnosis for men. Available from https:\/\/prostatecanceruk.org\/about-us\/projects-and-policies\/mpmri. Accessed 6th September 2020."},{"key":"449_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.eururo.2016.07.041","volume":"71","author":"O Wegelin","year":"2017","unstructured":"Wegelin O, van Melick HHE, Hooft L, Ruud Bosch JLH, Reitsma HB, Barentxz JO, et al. Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive regsitration. is there a preferred technique? Eur Urol. 2017;71:517\u201331.","journal-title":"Eur Urol"},{"key":"449_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"key":"449_CR8","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","volume":"22","author":"JO Barentsz","year":"2012","unstructured":"Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs, et al. ESUR prostate MR guidelines 2012. Eur Radio. 2012;22:746\u201357.","journal-title":"Eur Radio"},{"issue":"Oct","key":"449_CR9","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(Oct):529\u201336. 18","journal-title":"Ann Intern Med"},{"key":"449_CR10","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2013.03.030","volume":"64","author":"CM Moore","year":"2013","unstructured":"Moore CM, Kasivisvanathan V, Eggener S, Emberton M, F\u00fctterer JJ, Gill IS, et al. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: Recommendations from an international working group. Eur Urol. 2013;64:544\u201352.","journal-title":"Eur Urol"},{"key":"449_CR11","unstructured":"Altman D, Machin D, Bryant TN & Gardner MJ. Statistics with confidence: confidence intervals and statistical guidelines. 2nd ed. BMJ Books; 2000."},{"key":"449_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"449_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1442-2042.2010.02612.x","volume":"17","author":"T Miyagawa","year":"2010","unstructured":"Miyagawa T, Ishikawa S, Kimura T, Suetomi T, Tsutsumi M, Irie T, et al. Real-time virtual sonography for navigation during targeted prostate biopsy using magnetic resonance imaging data. Int J Urol. 2010;17:855\u201360.","journal-title":"Int J Urol"},{"key":"449_CR14","doi-asserted-by":"publisher","first-page":"W876","DOI":"10.2214\/AJR.11.6829","volume":"197","author":"BK Park","year":"2011","unstructured":"Park BK, Park JW, Park SY, Kim CK, Lee HM, Jeon SS, et al. Prospective evaluation of 3-T MRI performed before initial transrectal ultrasound-guided prostate biopsy in patients with high prostate-specific antigen and no previous biopsy. AJR Am J Roentgenol. 2011;197:W876\u2013W881.","journal-title":"AJR Am J Roentgenol"},{"key":"449_CR15","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.eururo.2012.06.044","volume":"62","author":"D Portalez","year":"2012","unstructured":"Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol. 2012;62:986\u201396.","journal-title":"Eur Urol"},{"key":"449_CR16","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.juro.2012.08.025","volume":"188","author":"S Vourganti","year":"2012","unstructured":"Vourganti S, Rastinehad A, Yerram NK, Nix J, Volkin D, Hoang A, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012;188:2152\u20137.","journal-title":"J Urol"},{"key":"449_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.juro.2012.08.195","volume":"189","author":"NB Delongchamps","year":"2013","unstructured":"Delongchamps NB, Peyromaure M, Schull A, Beuvon F, Bouazza N, Flam T, et al. Prebiopsy magnetic resonance imaging and prostate cancer detection comparison of random and targeted biopsies. J Urol. 2013;189:493\u20139.","journal-title":"J Urol"},{"key":"449_CR18","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.urology.2013.02.022","volume":"81","author":"G Fiard","year":"2013","unstructured":"Fiard G, Hohn N, Descotes JL, Rambeaud JJ, Troccaz J, Long JA. Targeted MRI-guided prostate biopsies for the detection of prostate cancer: initial clinical experience with real-time 3-dimensional transrectal ultrasound guidance and magnetic resonance\/transrectal ultrasound image fusion. Urology. 2013;81:1372\u20138.","journal-title":"Urology"},{"key":"449_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/bju.13023","volume":"116","author":"A Borkowetz","year":"2015","unstructured":"Borkowetz A, Platzek I, Toma M, Laniado M, Baretton G, Froehner M, et al. Comparison of systematic transrectal biopsy to transperineal magnetic resonance imaging\/ultrasound-fusion biopsy for the diagnosis of prostate cancer. BJU Int. 2015;116:873\u20139.","journal-title":"BJU Int"},{"key":"449_CR20","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.juro.2013.04.043","volume":"190","author":"TH Kuru","year":"2013","unstructured":"Kuru TH, Roethke MC, Seidenader J, Simpfend\u00f6rfer T, Boxler S, Alammar K, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol. 2013;190:1380\u20136.","journal-title":"J Urol"},{"key":"449_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1148\/radiol.13121501","volume":"268","author":"P Puech","year":"2013","unstructured":"Puech P, Rouviere O, Renard-Penna R, Villers A, Devos P, Colombel M, et al. Prostate cancer diagnosis: Multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy \u2013 prospective multicenter study. Radiology. 2013;268:461\u20139.","journal-title":"Radiology"},{"key":"449_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.eururo.2013.10.048","volume":"66","author":"JS Wysock","year":"2014","unstructured":"Wysock JS, Rosenkrantz AB, Huang WC, Stifelman MD, Lepor H, Deng FH, et al. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of the MR-targeted prostate biopsy: The PROFUS trial. Eur Urol. 2014;66:343\u201351.","journal-title":"Eur Urol"},{"key":"449_CR23","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1002\/cncr.28790","volume":"120","author":"SS Salami","year":"2014","unstructured":"Salami SS, Vira MA, Turkbey B, Fakhoury M, Yaskiv O, Villani R, et al. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer. Cancer. 2014;120:2876\u201382.","journal-title":"Cancer"},{"key":"449_CR24","first-page":"53","volume":"57","author":"H Iwamoto","year":"2014","unstructured":"Iwamoto H, Yumioka T, Yamaguchi N, Inoue S, Masago T, Morizane S, et al. The efficacy of target biopsy of suspected cancer lesions detected by magnetic resonance imaging and\/or transrectal ultrasonography during initial prostate biopsies: comparison of outcomes between two physicians. Yonago Acta Med. 2014;57:53\u201358.","journal-title":"Yonago Acta Med"},{"key":"449_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2014.03.002","volume":"66","author":"MR Pokorny","year":"2014","unstructured":"Pokorny MR, de Rooji M, Duncan E, Schr\u00f6der FH, Parkinson R, Barentsz JO, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014;66:22\u201329.","journal-title":"Eur Urol"},{"key":"449_CR26","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.juro.2014.05.090","volume":"192","author":"M Quentin","year":"2014","unstructured":"Quentin M, Blondin D, Arsov C, Schimm\u00f6ller L, Hiester A, Godehardt E, et al. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naive men with elevated prostate specific antigen. J Urol. 2014;192:1374\u20139.","journal-title":"J Urol"},{"key":"449_CR27","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.juro.2013.12.007","volume":"191","author":"AR Rastinehad","year":"2014","unstructured":"Rastinehad AR, Turkbey B, Salami SS, Yaskiv O, George AK, Fakhoury M, et al. Improving detection of clinically significant prostate cancer: magnetic resonance imaging\/transrectal ultrasound fusion guided prostate biopsy. J Urol. 2014;191:1749\u201354.","journal-title":"J Urol"},{"key":"449_CR28","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.juro.2014.08.002","volume":"192","author":"NA Shakir","year":"2014","unstructured":"Shakir NA, George AK, Siddiqui M, Rothwax JT, Rais-Bahrami S, Stamatakis L, et al. Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging\/ultrasound fusion guided biopsy. J Urol. 2014;192:1642\u20138.","journal-title":"J Urol"},{"key":"449_CR29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.eururo.2013.03.025","volume":"65","author":"GA Sonn","year":"2014","unstructured":"Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol. 2014;65:809\u201315.","journal-title":"Eur Urol"},{"key":"449_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000365397","volume":"94","author":"S Kaufman","year":"2015","unstructured":"Kaufman S, Kruck S, Kramer U, Gatidis S, Stenzl A, Roethke M, et al. Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies. Urol Int. 2015;94:319\u201325.","journal-title":"Urol Int"},{"key":"449_CR31","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/jmri.24682","volume":"41","author":"I Jambor","year":"2015","unstructured":"Jambor I, K\u00e4hk\u00f6nen E, Taimen P, Merisaari H, Saunavaara J, Alanen K, et al. Prebiopsy multiparametric 3T prostate MRI in patients with elevated PSA, normal digital rectal examination, and no previous biopsy. J Magn Reson Imaging. 2015;41:1394\u2013404.","journal-title":"J Magn Reson Imaging"},{"key":"449_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3109\/21681805.2014.925497","volume":"49","author":"L Boesen","year":"2015","unstructured":"Boesen L, Noergaard N, Chabanova E, Logager V, Balslev I, Mikines K, et al. Early experience with multiparametric magnetic resonance imaging for predicting biopsy results in first or repeat biopsy. Scand J Urol. 2015;49:25\u201334.","journal-title":"Scand J Urol"},{"key":"449_CR33","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bju.12938","volume":"115","author":"SS Salami","year":"2015","unstructured":"Salami SS, Ben-Levi E, Yaskiv O, Tyniker L, Turkbey B, Kavoussi LR, et al. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy? BJU Int. 2015;115:562\u201370.","journal-title":"BJU Int"},{"key":"449_CR34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/iju.12643","volume":"22","author":"S Shoji","year":"2015","unstructured":"Shoji S, Hiraiwa S, Endo J, Hashida K, Tomonage T, Nakano M, et al. Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric resonance imaging and transrectal ultrasound: an early experience. Int J Urol. 2015;22:173\u20138.","journal-title":"Int J Urol"},{"key":"449_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bju.12690","volume":"115","author":"P Mozer","year":"2015","unstructured":"Mozer P, Roupr\u00eat M, Le Cossec C, Granger B, Comperat E, de Gorski A, et al. First round of targeted biopsies using magnetic resonance imaging\/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localized prostate cancer. BJU Int. 2015;115:50\u201357.","journal-title":"BJU Int"},{"key":"449_CR36","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.1016\/j.clgc.2014.06.013","volume":"13","author":"P Pepe","year":"2015","unstructured":"Pepe P, Garufi A, Priolo G, Pennisi M. Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA <10 ng\/mL? Clin Genitourin Cancer. 2015;13:e27\u2013e30.","journal-title":"Clin Genitourin Cancer"},{"key":"449_CR37","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.eururo.2015.06.008","volume":"68","author":"C Arsov","year":"2015","unstructured":"Arsov C, Rabenalt R, Blondin D, Quentin M, Hiester A, Godehardt E, et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. Eur Urol. 2015;68:713\u201320.","journal-title":"Eur Urol"},{"key":"449_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00345-015-1671-8","volume":"34","author":"H Cash","year":"2016","unstructured":"Cash H, Maxeiner A, Stephan C, Fischer T, Durmus T, Holzmann J, et al. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI\/transrectal ultrasound fusion biopsy. World J Urol. 2016;34:525\u201332.","journal-title":"World J Urol"},{"key":"449_CR39","doi-asserted-by":"publisher","first-page":"416.e9","DOI":"10.1016\/j.urolonc.2016.04.008","volume":"34","author":"GC Mariotti","year":"2016","unstructured":"Mariotti GC, Costa DN, Pedrosa I, Falsarella PM, Martins T, Roehrborn CG, et al. Magnetic resonance\/transrectal ultrasound fusion biopsy of the prostate compared to systematic 12-core biopsy for the diagnosis and characterization of the prostate cancer: multi-institutional retrospective analysis of 389 patients. Urol Oncol. 2016;34:416.e9\u2013416.e14.","journal-title":"Urol Oncol"},{"key":"449_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.5489\/cuaj.3831","volume":"10","author":"DW Cool","year":"2016","unstructured":"Cool DW, Romagnoli C, Izawa JI, Chin J, Gardi L, Tessier D, et al. Comparison of prostate MRI-3D transrectal ultrasound fusion biopsy for first-time and repeat biopsy patients with previous atypical small acinar proliferation. Can Urol Assoc J. 2016;10:342\u20138.","journal-title":"Can Urol Assoc J"},{"key":"449_CR41","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1159\/000477214","volume":"99","author":"L Boesen","year":"2017","unstructured":"Boesen L, N\u00f8rgaard N, L\u00f8gager V, Balslev I, Thomsen HS. A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies. Urol Int. 2017;99:384\u201391.","journal-title":"Urol Int"},{"key":"449_CR42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.diii.2017.06.010","volume":"98","author":"J Garcia Bennett","year":"2017","unstructured":"Garcia Bennett J, Vilanova JC, Gum\u00e0 Padr\u00f3 J, Parada D, Conejero A. Evaluation of MR imaging-targeted biopsies of the prostate in biopsy-na\u00efve patients. A single centre study. Diagn Inter Imaging. 2017;98:677\u201384.","journal-title":"Diagn Inter Imaging"},{"key":"449_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/bju.14017","volume":"121","author":"A Borkowetz","year":"2018","unstructured":"Borkowetz A, Hadaschik B, Platzek I, Toma M, Torsev G, Renner T, et al. Prospective comparison of transperineal magnetic resonance imaging\/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-na\u00efve patients. BJU Int. 2018;121:53\u201360.","journal-title":"BJU Int"},{"key":"449_CR44","doi-asserted-by":"publisher","first-page":"E330","DOI":"10.5489\/cuaj.4308","volume":"11","author":"F Bladou","year":"2017","unstructured":"Bladou F, Fogaing C, Levental M, Aronson S, Alameldin M, Anidjar M. Transrectal ultrasound-guided biopsy for prostate cancer detection: systematic and-or magnetic-resonance imaging-targeted. Can Urol Assoc J. 2017;11:E330\u2013E337.","journal-title":"Can Urol Assoc J"},{"key":"449_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejrad.2016.11.016","volume":"86","author":"A Jelidi","year":"2017","unstructured":"Jelidi A, Ohana M, Labani A, Alemann G, Lang H, Roy C. Prostate cancer diagnosis: efficacy of a simple electromagnetic MRI-TRUS fusion method to target biopsies. Eur J Radio. 2017;86:127\u201334.","journal-title":"Eur J Radio"},{"key":"449_CR46","doi-asserted-by":"publisher","first-page":"341.e1","DOI":"10.1016\/j.urolonc.2018.04.002","volume":"36","author":"A Sidana","year":"2018","unstructured":"Sidana A, Watson MJ, George AK, Rastinehad AR, Vourganti S, Rais-Bahrami S, et al. Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis. Urol Oncol. 2018;36:341.e1\u2013341.e7.","journal-title":"Urol Oncol"},{"key":"449_CR47","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.juro.2018.02.067","volume":"200","author":"A Mortezavi","year":"2018","unstructured":"Mortezavi A, M\u00e4rzendorfer O, Donati OF, Rizzi G, Rupp NJ, Wettstein MS, et al. Diagnostic accuracy of multiparametric resonance imaging and fusion guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer. J Urol. 2018;200:309\u201318.","journal-title":"J Urol"},{"key":"449_CR48","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/21681805.2018.1438509","volume":"52","author":"A Fourcade","year":"2018","unstructured":"Fourcade A, Payrard C, Tissot V, Perrouin-Verbe MA, Demany N, Serey-Effeil S, et al. The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer. Scand J Urol. 2018;52:174\u20139.","journal-title":"Scand J Urol"},{"key":"449_CR49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.5152\/tud.2019.03710","volume":"45","author":"G S\u00f6nmez","year":"2019","unstructured":"S\u00f6nmez G, Tombul ST, \u0130mamo\u011flu H, Akg\u00fcn H, Demirta\u015f A, Tatl\u0131\u015fen A. Multiparametric MRI fusion-guided prostate biopsy in biopsy na\u00efve patients: Preliminary results from 80 patients. Turk J Urol. 2019;45:196\u2013201.","journal-title":"Turk J Urol"},{"key":"449_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clinimag.2018.09.012","volume":"53","author":"SI Hwang","year":"2019","unstructured":"Hwang SI, Lee HJ, Lee SE, Hong SK, Byun SS, Lee SC, et al. Value of MR-US fusion in guidance of repeated prostate biopsy in men with PSA<10ng\/mL. Clin Imaging. 2019;53:1\u20135.","journal-title":"Clin Imaging"},{"key":"449_CR51","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.euo.2019.06.005","volume":"3","author":"L Exterkate","year":"2020","unstructured":"Exterkate L, Wegelin O, Barentsz JO, van der Leest MG, Kummer JA, Vreuls W. Is there still a need for repeated systematic biopsies in patients with previous negative biopsies in the era of magnetic resonance imaging-targeted biopsies of the prostate? Eur Urol Oncol. 2020;3:216\u201323.","journal-title":"Eur Urol Oncol"},{"key":"449_CR52","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"M Van der Leest","year":"2019","unstructured":"Van der Leest M, Cornel E, Isra\u00ebl B, Hendricks R, Padhani AR, Hoogenboom M, et al. Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-na\u00efve men with elevated prostate-specific antigen: a large prospective multicenter clinical study. Eur Urol. 2019;75:570\u20138.","journal-title":"Eur Urol"},{"key":"449_CR53","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino D, Mineo Bianchi F, Romagnoli D, Corsi P, Giampaoli M, Schiavina R et al. Comparison between \u201cIn-bore\u201d MRI guided prostate biopsy and standard ultrasound guided biopsy in the patient with suspicious prostate cancer: Preliminary results. Arch Ital Urol Androl. 2019;91:4.","DOI":"10.4081\/aiua.2019.2.87"},{"key":"449_CR54","doi-asserted-by":"publisher","first-page":"156","DOI":"10.4111\/icu.2019.60.3.156","volume":"60","author":"R Kaushal","year":"2019","unstructured":"Kaushal R, Das CJ, Singh P, Dogra PN, Jumar R. Multiparametric magnetic resonance imaging-transrectal ultrasound fusion biopsies increase the rate of cancer detection in populations with a low incidence of prostate cancer. Investig Clin Urol. 2019;60:156\u201361.","journal-title":"Investig Clin Urol"},{"key":"449_CR55","doi-asserted-by":"publisher","first-page":"298.e1","DOI":"10.1016\/j.urolonc.2019.01.005","volume":"37","author":"CK Mannaerts","year":"2019","unstructured":"Mannaerts CK, Kajtazovic A, Lodeizen OAP, Gayet M, Engelbrecht MRW, Jager GJ, et al. The added value of systematic biopsy in men with suspicion of prostate cancer undergoing multiparametric MRI-targeted biopsy. Urol Oncol. 2019;37:298.e1\u2013298.e9.","journal-title":"Urol Oncol"},{"key":"449_CR56","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378:1767\u201377.","journal-title":"N Engl J Med"},{"key":"449_CR57","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamasurg.2019.1734","volume":"154","author":"FF Elkhhoury","year":"2019","unstructured":"Elkhhoury FF, Felker ER, Kwan L, Sisk AE, Delfin M, Natarajan S, et al. Comparison of targeted vs systematic prostate biopsy in men who are biopsy na\u00efve. the prospective assessment of image registration in the diagnosis of the prostate cancer (PAIREDCAP) study. JAMA Surg. 2019;154:811\u20138.","journal-title":"JAMA Surg"},{"key":"449_CR58","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1910038","volume":"382","author":"M Ahdoot","year":"2020","unstructured":"Ahdoot M, Wilbut AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. N Engl J Med. 2020;382:917\u201328.","journal-title":"N Engl J Med"},{"key":"449_CR59","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","volume":"75","author":"O Wegelin","year":"2019","unstructured":"Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, et al. The FUTURE Trial: a multicenter randomised controlled trial on target biopsy technique based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies. Eur Urol. 2019;75:582\u201390.","journal-title":"Eur Urol"},{"key":"449_CR60","doi-asserted-by":"publisher","unstructured":"Bass EJ, Orczyk C, Grey A, Freeman A, Jameson C, Punwani S et al. Targeted biopsy of the prostate: does this results in improvement in detection of high-grade cancer or the occurrence of the Will Rogers phenomenon? BJU Int. 2019 May 13 https:\/\/doi.org\/10.1111\/bju.14806. [Epub ahead of print]","DOI":"10.1111\/bju.14806."},{"key":"449_CR61","doi-asserted-by":"publisher","first-page":"e2019007","DOI":"10.4178\/epih.e2019007","volume":"41","author":"S Shim","year":"2019","unstructured":"Shim S, Kim SJ, Lee J. Diagnostic test accuracy: application and practice using R software. Epidemiol Health. 2019;41:e2019007.","journal-title":"Epidemiol Health"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00449-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00449-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00449-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:12:02Z","timestamp":1656936722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-021-00449-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1038\/s41391-021-00449-7","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HUA\u2019s research is supported by core funding from the United Kingdom\u2019s National Institute of Health Research (NIHR) Imperial Biomedical Research Centre. HUA currently receives funding from the Wellcome Trust, Medical Research Council (UK), Cancer Research UK, Prostate Cancer UK, The Urology Foundation, BMA Foundation, Imperial Health Charity, NIHR Imperial BRC, Sonacare Inc., Trod Medical and Sophiris Biocorp for trials in prostate cancer. HUA was a paid medical consultant for Sophiris Biocorp in the previous 3 years. HUA receives fees for proctoring in cryotherapy (Boston), Rezum (Boston) and HIFU (Sonacare Inc). SL is supported by the Prostate Cancer Foundation. RA receives research support from Philips Healthcare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}